{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:34:22Z","timestamp":1790130862983,"version":"4.0.1"},"reference-count":177,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.critrevonc.2007.06.011","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T11:53:21Z","timestamp":1187092401000},"page":"129-142","source":"Crossref","is-referenced-by-count":205,"title":["The management of patients with uterine sarcoma: A debated clinical challenge"],"prefix":"10.1016","volume":"65","author":[{"given":"Angiolo","family":"Gadducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Romanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Riccardo","family":"Genazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2007.06.011_bib1","first-page":"399","article-title":"The epidemiology of sarcomas of the uterus","volume":"76","author":"Harlow","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0959-8049(97)00040-3","article-title":"Uterine sarcomas in Norway 1956\u20131992: incidence, survival and mortality","volume":"33","author":"Nordal","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989\u20131999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0360-3016(80)90334-X","article-title":"The role of radiation therapy in the management of uterine sarcomas","volume":"6","author":"Salazar","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib5","first-page":"845","article-title":"Treatment of uterine leiomyosarcoma","volume":"71","author":"Berchuck","year":"1988","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0090-8258(89)80027-7","article-title":"Endometrial stromal sarcoma: a report of nine cases","volume":"32","author":"Taina","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0090-8258(90)90109-X","article-title":"Treatment of endometrial stromal tumors","volume":"36","author":"Berchuck","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1525-1438.1993.03010001.x","article-title":"Mixed mullerian tumors of the uterine corpus: a review","volume":"3","author":"Ali","year":"1993","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.1996.0314","article-title":"Endometrial stromal sarcoma: analysis of treatment failures and survival","volume":"63","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/gyno.1997.4827","article-title":"Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study","volume":"67","author":"Sartori","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<512::AID-CNCR13>3.3.CO;2-K","article-title":"Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients","volume":"82","author":"Iwasa","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib13","first-page":"295","article-title":"The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases","volume":"23","author":"Gadducci","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2005.09.017","article-title":"Clinical features and outcomes of uterine and ovarian carcinosarcoma","volume":"100","author":"Jonson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib15","first-page":"173","article-title":"Uterine endolymphatic stromal myosis: a collaborative study","volume":"64","author":"Piver","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-8258(89)90002-4","article-title":"Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945\u20131980","volume":"35","author":"De Fusco","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00125480-200007050-00001","article-title":"Endometrial stromal tumors: an update on a group of tumors with a protean phenotype","volume":"7","author":"Oliva","year":"2000","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2004.07.021","article-title":"The classification of a uterine sarcoma as \u2018high-grade endometrial stromal sarcoma\u2019 should be abandoned","volume":"95","author":"Amant","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00313020601136146","article-title":"Uterine sarcomas","volume":"39","author":"Moinfar","year":"2007","journal-title":"Pathology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0344-0338(00)80045-X","article-title":"Detection of pulmonary metastasis of low-grade endometrial stromal sarcoma 25 years after hysterectomy","volume":"196","author":"Inayama","year":"2000","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2176\/nmc.36.469","article-title":"Uterine leiomyosarcoma metastasis to the skull\u2013case report","volume":"36","author":"Uchino","year":"1996","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0029-7844(98)00137-9","article-title":"Metastatic uterine leiomyosarcoma presenting as a primary sarcoma of the parotid gland","volume":"92","author":"Saiz","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ygyno.2003.11.049","article-title":"Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection","volume":"92","author":"Yokoyama","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anchir.2005.06.007","article-title":"Duodenal metastatic leiomyosarcoma of the uterus. A case report","volume":"130","author":"M'sakni","year":"2005","journal-title":"Ann Chir"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1447-0756.2005.00344.x","article-title":"Metastasis of uterine leiomyosarcoma to the pancreas","volume":"31","author":"Iwamoto","year":"2005","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1470-2045(05)70543-X","article-title":"Pancreatic metastasis from leiomyosarcoma of the broad ligament of the uterus","volume":"7","author":"Falconi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO;2-V","article-title":"Treatment of uterine sarcomas","volume":"66","author":"Echt","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/gyno.1994.1011","article-title":"A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas","volume":"52","author":"Wolfson","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1471-0528.1992.tb13827.x","article-title":"Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma","volume":"99","author":"Olah","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2559.2001.01300.x","article-title":"Recent advanced in the pathology of smooth mucle tumours of the uterus","volume":"39","author":"Wilkinson","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00000478-199406000-00001","article-title":"Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases","volume":"18","author":"Bell","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0968-6053(03)00072-3","article-title":"Uterine smooth-muscle tumours: practical approach to diagnosis","volume":"10","author":"Al-Nafussi","year":"2004","journal-title":"Curr Diagn Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib33","series-title":"Blaustein's pathology of the female genital tract","first-page":"561","article-title":"Mesenchymal tumors of the uterus","author":"Zaloudek","year":"2002"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/0002-9378(90)91298-Q","article-title":"Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas","volume":"162","author":"Leibsohn","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2007.06.011_bib35","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0090-8258(90)90267-O","article-title":"Uterine sarcoma: steroid receptors and response to hormonal therapy","volume":"39","author":"Wade","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00004347-199901000-00004","article-title":"Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas","volume":"18","author":"Zhai","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib38","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/hupa.2001.27113","article-title":"MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors","volume":"32","author":"Mittal","year":"2001","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsbmb.2003.11.013","article-title":"Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters","volume":"88","author":"Kitaoka","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib40","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.20521","article-title":"Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma","volume":"101","author":"Leitao","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2005.05.019","article-title":"The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study","volume":"99","author":"Akhan","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib42","first-page":"729","article-title":"Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters","volume":"23","author":"Bodner","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004347-200304000-00011","article-title":"Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary","volume":"22","author":"Klein","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2003.06.001","article-title":"Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus","volume":"91","author":"Winter","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0090-8258(03)00274-9","article-title":"The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus","volume":"90","author":"Wang","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib46","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1158\/1078-0432.CCR-03-0363","article-title":"c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment","volume":"10","author":"Raspollini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.pgp.0000183047.45459.36","article-title":"Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region","volume":"25","author":"Nakayama","year":"2006","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0090-8258(03)00442-6","article-title":"Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT","volume":"91","author":"Rushing","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2004.09.035","article-title":"Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT","volume":"98","author":"Raspollini","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib50","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1158\/1078-0432.CCR-04-2461","article-title":"Imatinib is not a potential alternative treatment for uterine leiomyosarcoma","volume":"11","author":"Serrano","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2004.07.041","article-title":"ERBB-2 gene overexpression and amplification in uterine sarcomas","volume":"95","author":"Amant","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1699-0463.1996.tb04932.x","article-title":"Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus)","volume":"104","author":"Sprogoe-Jakobsen","year":"1996","journal-title":"APMIS"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/gyno.1994.1194","article-title":"p53 alterations in uterine leiomyosarcomas versus leiomyomas","volume":"54","author":"de Vos","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/path.1711770111","article-title":"p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus","volume":"177","author":"Jeffers","year":"1995","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/gyno.1997.4653","article-title":"Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas","volume":"65","author":"Hall","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib56","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1525-1438.2006.00542.x","article-title":"p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas","volume":"16","author":"Anderson","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/j.0001-6349.2004.00502.x","article-title":"Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS)","volume":"83","author":"Mayerhofer","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.pas.0000180424.75077.a3","article-title":"Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors","volume":"30","author":"Esposito","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2005.07.017","article-title":"Array comparative genomic hybridization analysis of uterine leiomyosarcoma","volume":"99","author":"Cho","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00000478-199005000-00002","article-title":"Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases","volume":"14","author":"Chang","year":"1990","journal-title":"Am J Surg Pathol Am Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib61","first-page":"255","article-title":"Endolymphatic stromal myosis: surgical and hormonal therapy for extensive venous recurrence Gynecol","volume":"33","author":"Montag","year":"1989","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib62","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1054\/bjoc.1999.1038","article-title":"Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas","volume":"82","author":"Reich","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0090-8258(03)00258-0","article-title":"Low-grade endometrial stromal sarcoma: hormonal aspects","volume":"90","author":"Chu","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib64","series-title":"Hormone replacement therapy and cancer. The current status of research and practice","first-page":"148","article-title":"Endometrial stromal tumors-are they hormonally sensitive?","author":"Schwartz","year":"2002"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-200404000-00008","article-title":"Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma","volume":"23","author":"Balleine","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib66","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib67","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.pas.0000155149.83541.24","article-title":"Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach","volume":"29","author":"Moinfar","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib68","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/jcp.2006.044842","article-title":"Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers","volume":"60","author":"Hurrell","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004280100455","article-title":"Uterine tumor resembling ovarian sex-cord tumor\u2014a case report and review of the literature","volume":"439","author":"Hauptmann","year":"2001","journal-title":"Virchows Arch"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib70","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.pai.0000129057.38941.a1","article-title":"Imatinib mesylate (gleevec)\u2013targeted kinases are expressed in uterine sarcomas","volume":"13","author":"Caudell","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib71","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0090-8258(89)90176-5","article-title":"Clinicopathologic analysis of uterine malignant mixed mullerian tumors","volume":"34","author":"Nielsen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib72","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(20000615)88:12<2782::AID-CNCR17>3.0.CO;2-K","article-title":"Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus","volume":"88","author":"Yamada","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib73","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<821::AID-IJC19>3.0.CO;2-B","article-title":"Uterine carcinosarcoma is derived from a single stem cell: an in vitro study","volume":"72","author":"Gorai","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004347-199001000-00001","article-title":"Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases","volume":"9","author":"Silverberg","year":"1990","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00000478-199506000-00007","article-title":"Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis","volume":"19","author":"Sreenan","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib76","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0277-5379(87)90145-3","article-title":"Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract","volume":"23","author":"Jansen","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0090-8258(89)90166-2","article-title":"Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors","volume":"34","author":"Peters","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib78","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.1991.9.11.1962","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study","volume":"9","author":"Thigpen","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00000421-199106000-00012","article-title":"Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary","volume":"14","author":"Baker","year":"1991","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib80","first-page":"45","article-title":"Presentation and management of carcinosarcoma of the uterus","volume":"6","author":"Vaccarello","year":"1992","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1438.1994.04010052.x","article-title":"The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract","volume":"4","author":"van Rijswijk","year":"1994","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/gyno.1997.4629","article-title":"Uterine carcinosarcomas: incidence and trends in management and survival","volume":"65","author":"Arrastia","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0959-8049(02)00740-2","article-title":"Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)","volume":"39","author":"van Rijswijk","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib84","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","article-title":"Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib85","first-page":"606","article-title":"Mixed tumours of the uterus","volume":"Vol. 1","author":"\u00d6st\u00f6r","year":"1995"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib86","first-page":"421","article-title":"Endometrial hyperplasia, metaplasia, and carcinoma","volume":"Vol. 1","author":"Longracre","year":"1995"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib87","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2004.08.042","article-title":"Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma","volume":"95","author":"Emoto","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004347-199501000-00007","article-title":"Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival","volume":"14","author":"George","year":"1995","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2005.04.027","article-title":"Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer","volume":"98","author":"Amant","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib90","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1349-7006.2003.tb01389.x","article-title":"Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma","volume":"94","author":"Sawada","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2004.09.045","article-title":"Expression of c-kit in uterine carcinosarcoma","volume":"96","author":"Menczer","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2004.09.050","article-title":"COX-2, c-KIT and HER-2\/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?","volume":"96","author":"Raspollini","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib93","first-page":"823","article-title":"Identification of HER-2\/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma","volume":"10","author":"Riben","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib94","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib95","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib96","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1525-1438.2006.00410.x","article-title":"Expression and amplification of HER-2\/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?","volume":"16","author":"Raspollini","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib97","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2559.1994.tb00512.x","article-title":"p53 immunostaining suggests that uterine carcinosarcomas are monoclonal","volume":"24","author":"Mayall","year":"1994","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0.CO;2-2","article-title":"Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas","volume":"73","author":"Seki","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib99","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1048-891x.2004.014221.x","article-title":"Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma","volume":"14","author":"Abargel","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib100","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/modpathol.3800654","article-title":"DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis","volume":"19","author":"Taylor","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib101","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/erc.0.0100203","article-title":"Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer","volume":"10","author":"Terakawa","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib103","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.2002.6601","article-title":"PTEN mutations in uterine sarcomas","volume":"85","author":"Amant","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2005.11.002","article-title":"Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies","volume":"58","author":"Gadducci","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib106","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1297-9589(03)00061-4","article-title":"Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure","volume":"31","author":"Morice","year":"2003","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib107","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ygyno.2003.10.044","article-title":"The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990\u20131999) at the Massachusetts General Hospital","volume":"92","author":"Dinh","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejso.2005.01.010","article-title":"The role of surgery and treatment trends in uterine sarcoma","volume":"31","author":"Benoit","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib109","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2004.12.006","article-title":"A comparison between different postoperative treatment modalities of uterine carcinosarcoma","volume":"97","author":"Menczer","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2005.08.010","article-title":"Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma","volume":"100","author":"Wu","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib111","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/01.cco.0000127721.55676.f6","article-title":"Uterine leiomyosarcoma: present management","volume":"16","author":"Giuntoli","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/gyno.1993.1172","article-title":"Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence","volume":"50","author":"Goff","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib113","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1479-828X.1999.tb03453.x","article-title":"Management of uterine leiomyosarcoma in Australia","volume":"39","author":"Gard","year":"1999","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/gyno.1998.5124","article-title":"Fertility-sparing surgery in uterine leiomyosarcoma","volume":"70","author":"Lissoni","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ogc.2005.12.009","article-title":"Uterine artery embolization as a treatment option for uterine myomas","volume":"33","author":"Marshburn","year":"2006","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib116","first-page":"278","article-title":"Leiomyosarcoma after uterine artery embolization. A case report","volume":"46","author":"Joyce","year":"2001","journal-title":"J Reprod Med"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib117","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1438.2006.00762.x","article-title":"Early-stage carcinosarcoma of the uterus: the significance of lymph node count","volume":"17","author":"Temkin","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib118","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/01.AOG.0000185511.91694.1e","article-title":"Ovarian preservation in stage I low-grade endometrial stromal sarcomas","volume":"106","author":"Li","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib119","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2004.10.021","article-title":"Lymph node metastases in low-grade endometrial stromal sarcoma","volume":"96","author":"Riopel","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ygyno.2005.01.034","article-title":"Should lymphadenectomy be performed in patients with endometrial stromal sarcoma?","volume":"97","author":"Reich","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib121","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0090-8258(86)90226-X","article-title":"Adjuvant therapy in mixed mullerian tumors of the uterus","volume":"23","author":"Kohorn","year":"1986","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib122","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/gyno.1997.4676","article-title":"The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma","volume":"65","author":"Chi","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib123","first-page":"3069","article-title":"Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study","volume":"21","author":"Bodner-Adler","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.coc.0000156919.04133.98","article-title":"On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus","volume":"28","author":"Dusenbery","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clon.2004.01.010","article-title":"Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998","volume":"16","author":"Livi","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.1997.4901","article-title":"The impact of adjuvant radiotherapy on carcinosarcoma of the uterus","volume":"68","author":"Gerszten","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0167-8140(90)90100-B","article-title":"Mixed mullerian tumours of the uterus-prognostic factors: a clinical and histopathologic study of 147 cases","volume":"17","author":"Larson","year":"1990","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/ejso.2000.1104","article-title":"Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population","volume":"27","author":"Le","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000291889","article-title":"Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases","volume":"42","author":"Hoffmann","year":"1996","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib130","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1972::AID-CNCR13>3.0.CO;2-M","article-title":"Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri","volume":"83","author":"Knocke","year":"1998","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2007.06.011_bib131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ijgc-00009577-200303001-00012","article-title":"First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG study","volume":"13","author":"Reed","year":"2003","journal-title":"Int J Gynaecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib132","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","article-title":"High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence","volume":"15","author":"Patel","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib133","series-title":"American society of clinical oncology-2000 educational book, thirty-sixth annual meeting May 19\u201323","first-page":"453","article-title":"Dose-intensive chemotherapy for soft tissue sarcomas","author":"Patel","year":"2000"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib134","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jnci\/81.19.1496","article-title":"Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group-National Cancer Institute of Canada Clinical Trials Group","volume":"81","author":"Bramwell","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1989.7.9.1208","article-title":"Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy","volume":"7","author":"Elias","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib136","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","article-title":"An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas","volume":"11","author":"Antman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib137","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","article-title":"Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas","volume":"11","author":"Edmonson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib138","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","article-title":"Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"13","author":"Santoro","year":"1995","journal-title":"J Clin Oncol"},{"issue":"June 20 Supplement","key":"10.1016\/j.critrevonc.2007.06.011_bib139","article-title":"Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissue sarcoma (STS) patients","volume":"24","author":"Almeida","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2005.01.041","article-title":"Systemic therapy for advanced uterine sarcoma: a systematic review of the literature","volume":"97","author":"Kanjeekal","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib141","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib142","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib143","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0029-7844(96)00003-8","article-title":"Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group","volume":"87","author":"Sutton","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib144","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0002-9378(89)90507-3","article-title":"Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncologic Group study)","volume":"161","author":"Sutton","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib146","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1023\/A:1008464504583","article-title":"Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)","volume":"9","author":"Leyvraz","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib147","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib148","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib149","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2005.03.018","article-title":"Temozolomide in uterine leiomyosarcomas","volume":"98","author":"Anderson","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib151","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.cco.0000228740.70379.3f","article-title":"ET-743: a novel agent with activity in soft-tissue sarcomas","volume":"18","author":"Favette","year":"2006","journal-title":"Curr Opin Oncol"},{"issue":"June 20 Suppl.","key":"10.1016\/j.critrevonc.2007.06.011_bib152","article-title":"Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas","volume":"24","author":"Grosso","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib153","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib154","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/gyno.2001.6256","article-title":"Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"83","author":"Curtin","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib155","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ygyno.2004.05.048","article-title":"Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus","volume":"94","author":"Toyoshima","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib156","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study","volume":"25","author":"Homesley","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib157","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2005.05.015","article-title":"Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"98","author":"Miller","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib158","unstructured":"Adjuvant, chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-Analysis Collaboration (SMAC). Cochrane Database Syst Rev 2000; CD001419."},{"key":"10.1016\/j.critrevonc.2007.06.011_bib159","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2007.06.011_bib160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000073366","article-title":"Ifosfamide in the adjuvant therapy of soft tissue sarcomas","volume":"65","author":"Frustaci","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib161","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib162","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/1097-0142(19860415)57:8<1451::AID-CNCR2820570802>3.0.CO;2-Y","article-title":"Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study","volume":"57","author":"van Nagell","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib163","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00000421-199508000-00002","article-title":"Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial","volume":"18","author":"Hempling","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib164","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/gyno.1995.1065","article-title":"A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus","volume":"56","author":"Resnik","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib165","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1097-0142(20010415)91:8<1437::AID-CNCR1150>3.0.CO;2-P","article-title":"Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus","volume":"91","author":"Manolitsas","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib166","first-page":"352","article-title":"Adjuvant chemotherapy in early stage uterine sarcomas: an open question","volume":"22","author":"Gadducci","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1048-891X.2004.14420.x","article-title":"Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up","volume":"14","author":"Odunsi","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib168","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1048-891X.2004.14609.x","article-title":"Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone","volume":"14","author":"Pautier","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"June 20 Suppl.","key":"10.1016\/j.critrevonc.2007.06.011_bib169","article-title":"A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide+mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus","volume":"24","author":"Wolfson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0368-2315(05)82669-9","article-title":"Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide","volume":"34","author":"Paillocher","year":"2005","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib171","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1006\/gyno.1998.5174","article-title":"Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace","volume":"71","author":"Scribner","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib172","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.AOG.0000133533.05148.aa","article-title":"Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue","volume":"104","author":"Burke","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib173","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/gyno.2001.6238","article-title":"Endometrial stromal sarcoma: objective response to letrozole","volume":"82","author":"Maluf","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib174","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MO:20:1:87","article-title":"Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma","volume":"20","author":"Spano","year":"2003","journal-title":"Med Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9378(12)90910-2","article-title":"Leiomyosarcomas: clinical presentation","volume":"168","author":"Schwartz","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib176","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0090-8258(92)90286-R","article-title":"Resection of pulmonary metastases from uterine sarcomas","volume":"45","author":"Levenback","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2007.06.011_bib177","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/gyno.2001.6427","article-title":"Pulmonary resection in metastatic uterine and cervical malignancies","volume":"83","author":"Anderson","year":"2001","journal-title":"Gynecol Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T09:48:21Z","timestamp":1737366501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842807001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":177,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1040842807001357"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2007.06.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}